MODELLING BET INHIBITOR RESISTANCE IN ACUTE MYELOID LEUKAEMIA

Grant number: 1085015 | Funding period: 2015 - 2018

Completed

Abstract

Mutations in epigenetic regulators in AML not only imply a causative role for these proteins in AML but also provide potential targets for therapeutic intervention. One of the most promising epigenetic therapies to have emerged in the last decade are small molecule inhibitors targeted to the Bromodomain and Extra Terminal (BET) family of proteins. This proposal will elucidate the cellular and molecular mechanisms that drive resistance to this new class of drugs

Related publications (8)

University of Melbourne Researchers